Trials / Completed
CompletedNCT01627288
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Boost radiation | Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy |
Timeline
- Start date
- 2012-06-04
- Primary completion
- 2018-11-16
- Completion
- 2019-11-16
- First posted
- 2012-06-25
- Last updated
- 2021-02-08
- Results posted
- 2020-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01627288. Inclusion in this directory is not an endorsement.